Editas Medicine
EDIT
239 hedge funds and large institutions have $1.55B invested in Editas Medicine in 2020 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 84 increasing their positions, 58 reducing their positions, and 43 closing their positions.
132% more call options, than puts
Call options by funds: $33.3M | Put options by funds: $14.3M
45% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 58
2% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 43
0% more funds holding
Funds holding: 238 → 239 (+1)
0.24% less ownership
Funds ownership: 88.82% → 88.57% (-0.24%)
4% less capital invested
Capital invested by funds: $1.61B → $1.55B (-$61M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$102M |
| 2 |
BlackRock
New York
|
+$16.6M |
| 3 |
Goldman Sachs
New York
|
+$7.05M |
| 4 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$6.39M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$5.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$41.3M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$17.7M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$12.2M |
| 4 |
D.E. Shaw & Co
New York
|
-$9.04M |
| 5 |
State Street
Boston,
Massachusetts
|
-$5.64M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
276
Tradewinds Capital Management
Bellingham,
Washington
| – | -$3K | -100 | Closed |
|
|
EWP
277
Engrave Wealth Partners
The Woodlands,
Texas
| – | -$2K | -80 | Closed |
|
278
Lazard Asset Management
New York
| – | -$2K | -79 | Closed |
|
|
GEA
279
Glen Eagle Advisors
Kingston,
New Jersey
| – | -$2.22K | -75 | Closed |
|
|
EWM
280
Edge Wealth Management
New York
| – | -$1K | -25 | Closed |
|
|
IA
281
IFP Advisors
Tampa,
Florida
| – | -$33 | -1 | -10% |
|
|
BWM
282
Baystate Wealth Management
Boston,
Massachusetts
| – | +$358 | +11 | New |
|
EDIT Hedge Fund Activity: Q3 2020 in Review
239 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2020, worth a combined $1.55B — down 3.8% from $1.61B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new EDIT positions and 43 closed out — a net gain of 1 holder — while 84 added to existing stakes and 58 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $102M. The largest seller was CAAS Capital Management, exiting entirely with an estimated $41.3M sold.
- 239 institutional investors held Editas Medicine (EDIT) as of Q3 2020, up from 238 in Q2 2020.
- Funds reported $1.55B of Editas Medicine stock for Q3 2020, down 3.8% quarter-over-quarter.
- 44 funds opened new Editas Medicine positions in Q3 2020 and 43 closed out, a net change of +1 holder.
- The largest Editas Medicine buyer in Q3 2020 was ARK Investment Management, an estimated $102M added.
- The largest Editas Medicine seller in Q3 2020 was CAAS Capital Management, an estimated $41.3M sold.
Based on aggregated 13F filings for Q3 2020.